Accelerator for lean startups ending pediatric rare disease
Rare Pediatric Disease Patients Cannot Wait. So We Built Something That Moves at Their Speed.Somewhere right now, a parent is learning that their child has a rare disease affecting fewer than 1,000 people in the world and that no approved treatment exists.There is no pharmaceutical company working on it. There is no clinical trial to enroll in. There is no timeline for a cure. There is only the weight of a diagnosis, a child who needs help, and a system that was never designed to serve them.This is not an edge case. It is the daily reality of millions of families across the world. There are over 10,000 known rare diseases affecting more than 400 million people globally. Fewer than 10% of those diseases have a single FDA-approved treatment.Rare disease families pursue cures often by founding lean start-ups with a single purpose – develop an approved drug that can cure their child.
| Drug Development | Traditional | Lean |
|---|---|---|
| Time | 10 years | 3 years |
| Cost | $1B USD | $5M USD |
| Patient Population | hundreds of thousands - millions | one - thousands |
| Indication | broad | narrow |
| Infrastructure | R&D, manufacturing, sales, HR, etc. | CROs, partnerships, etc. |
*Traditional pharma spends $1B over 10 years to develop a drug. The average rare disease market is $200M. This is a structural mismatch that requires a different model. Rare disease family-founder must pursue lean drug development but are often limited by capital and infrastructure. 1000 Cures provides both in exchange for downstream PRV revenue.
2026 Legislation: Rare & Pediatric Drug DevelopmentThe FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program incentivizes the development of new drugs for rare pediatric diseases by awarding a voucher upon approval, which shortens the review period for a future drug application by 4 months. These vouchers can be sold, often for over $100 million, providing incentive to invest in cures for rare diseases that do not have large markets. The program was extended through September 30, 2029, under the Consolidated Appropriations Act, 2026.
1000 CuresCo-founder & CEO: Ethan Perlstein, Ph.D.Ethan received his Ph.D. in Molecular and Cell Biology from Harvard University, training under Prof. Stuart Schreiber, before completing an independent postdoctoral fellowship at Princeton University's Lewis-Sigler Institute. During his academic training, he developed an evolutionary approach to drug discovery in model organisms — methodology that anchored his subsequent career in translational science and patient-centered therapeutic development.Ethan went on to found Perlara PBC, the world's first biotech public benefit corporation, purpose-built to partner directly with rare disease families and patient communities to advance treatments — and a Y Combinator alumni company (W16). He later served as Chief Scientific Officer of the Christopher & Dana Reeve Foundation, where he managed a research portfolio
focused on moving promising therapies toward the clinic. As an investor in approximately 100 companies — with a top-performing investment returning 60x — Ethan brings the perspective of both a scientist and a builder.As Co-Founder & CEO of 1000 Cures, Ethan applies this depth of experience to help family founders turn scientific promise into focused, fundable, and executable development programs — building the ultra-lean accelerator model designed to shorten timelines, de risk execution, and deliver treatments to children with the urgency their situations demand.Co-founder & COO: Ryan Ponzi, Ph.DRyan received his B.S. in Chemistry from the University of New England and his Ph.D. in Organic Chemistry from Boston College, where he trained under Prof. Amir H. Hoveyda. Following his doctorate, Ryan made a deliberate transition from bench science to intellectual property law — motivated by a conviction that the most impactful contributions to drug development happened not only in the laboratory, but in the legal and business decisions that determine which science reaches patients.Ryan built his career at a Vault Top 5 IP law firm as a USPTO-registered Patent Agent, supporting major pharmaceutical and biotechnology clients in building and protecting high-value IP portfolios. He managed international IP portfolios for drug candidates and commercial products generating over $10 billion per year in revenue, and evaluated key assets for several multibillion-dollar biotech and pharmaceutical acquisitions — giving him an institutional understanding of how transformative science is valued, protected, and commercialized at every stage of development.As Co-Founder & COO of 1000 Cures, Ryan brings this precision to operationalizing the lean accelerator model — navigating the IP, regulatory, and capital challenges that are the rate-determining steps in every family founder's development journey, and compressing timelines in ways that matter to children who cannot afford to wait.
Family Founders & Partners
Coming soon
Whether you are a rare disease family founder navigating the development path for your child, a scientist or clinician who believes in this model, an investor seeking meaningful exposure to a government-validated biotech mechanism, or an organization working to advance rare disease innovation — there is a place for you in this mission.